Four-group classifcation of left ventricular hypertrophy based on ventricular concentricity and dilatation identifes a low-risk subset of eccentric hypertrophy in hypertensive patients

Circulation: Cardiovascular Imaging

Volumn 7, Issue 3, 2014, Pages 422-429

  Bang, Casper N ^a,b   Gerdts, Eva ^a,c   Aurigemma, Gerard P ^d   Boman, Kurt ^e   De Simone, Giovanni ^f   Dahlöf, Björn ^g   Køber, Lars ^b   Wachtell, Kristian ^a,h   Devereux, Richard B ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hypertension; Hypertrophy; Left ventricular geometry

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; LOSARTAN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HUMAN; HYPERTENSION; HYPERTROPHY; LEFT VENTRICULAR GEOMETRY; MALE; METHODOLOGY; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

HYPERTENSION; HYPERTROPHY; LEFT VENTRICULAR GEOMETRY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CAUSE OF DEATH; DEATH; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGAN SIZE; PROPORTIONAL HAZARDS MODELS; STROKE;

EID: 84904196362     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.001275     Document Type: Article

References (32)

1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
3. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960;5:370-382.
4. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classifcation of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010;3:164-171.
5. Chinali M, Aurigemma GP. Refning patterns of left ventricular hypertrophy using cardiac MRI: "brother, can you spare a paradigm?". Circ Cardiovasc Imaging. 2010;3:129-131.
6. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Blood Press. 2001;10:74-82.
7. Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, Roman MJ, Papademetriou V, Ibsen H, Rokkedal J, Devereux RB. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension. 2000;35(1 Pt 1):6-12.
8. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10(7 Pt 1):705-713.
9. Okin PM, Roman MJ, Devereux RB, Kligfeld P. Electrocardiographic identifcation of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantifcation: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantifcation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
11. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventricular size and function by echocardiography. Results in normal children. Circulation. 1977;56:457-462.
12. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identifcation of severe valvular aortic stenosis in adult patients. Am Heart J. 1982;103:202-203.
13. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardio-graphic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7-11.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy fndings. Am J Cardiol. 1986;57:450-458.
15. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, Paranicas M, Fishman D, Devereux RB. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999;34:1625-1632.
16. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451.
17. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J. 1990;120:116-123.
18. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M, Lee ET, Fabsitz RR, Welty TK, Howard BV, Devereux RB. Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. J Am Coll Cardiol. 2000;36:461-467.
19. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr. 2008;9:809-815.
20. Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Roman MJ, Køber L, Wachtell K, Devereux RB. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2013;31:2060-2068.
21. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. 1995;25:83-90.
22. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
23. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators. Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. Eur J Heart Fail. 2011;13:384-391.
24. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators. Regression of elec-trocardiographic left ventricular hypertrophy is associated with less hos-pitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147:311-319.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifcation and beyond. Stat Med. 2008;27:157-172; discussion 207.
26. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocar-dial iNfarcTion) Echocardiographic Study. J Am Coll Cardiol Cardiovasc Imaging. 2008;1:582-591.
27. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic signifcance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25:871-878.
28. Ghali JK, Liao Y, Cooper RS. Infuence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998;31:1635-1640.
29. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879-884.
30. Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F, Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens. 2004;17(11 Pt 1):1035-1039.
31. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol. 2002;39:664-671.
32. Roman MJ, Ganau A, Saba PS, Pini R, Pickering TG, Devereux RB. Impact of arterial stiffening on left ventricular structure. Hypertension. 2000;36:489-494.